Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)

Inclusion Criteria: * Adult or Pediatric persons with inherited Glanzmann thrombasthenia (see diagnostic criteria below) * Severe bleeding phenotype * Adequate hepatic function * Adequate renal function * Adults subject (≥18 years of age) or caregiver (parent or legally authorized representative) for minor subjects, subjects with cognitive impairment, or subjects with impaired decision-making capacity have provided written informed consent, and the participant has given consent/assent (if applicable) * Ability to speak, read, and understand the English language Exclusion Criteria: * Thrombocytopenia (platelet count \< 100k) * Acquired Glanzmann thrombasthenia secondary to autoimmune disease, malignancy, or medication * Inherited or acquired bleeding diathesis other than Glanzmann thrombasthenia * Have a history of venous or arterial thrombotic event within 2 years of study enrollment * Active malignancy * Known or suspected hypersensitivity to rabbits, rabbit protein, other forms of rFVIIa, or to any of the EB excipients * Have received an investigational drug within 30 days or within 5 half-lives of that investigational drug (whichever is longer) or are expected to receive such a drug during participation in this study * Be using aspirin, non-steroidal anti-inflammatory drugs (NSAIDS), herbs, natural medications, or other drugs with platelet inhibitor properties for the duration of the study * Be using or administered anticoagulant agents for the duration of the study * Have any life-threatening disease or other disease or condition which, according to the investigator's judgement, could imply a potential hazard to the patient, or interfere with the study participation or study outcome * Use of systemic immunomodulators at enrollment or planned use during the study